U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ceftolozane Tazobactam – Injection products
  1. Development Resources

Ceftolozane Tazobactam – Injection products

Recognized Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

M-100 standard is recognized

Pseudomonas aeruginosa

M-100 standard is recognized

Streptococcus spp Viridans
Group

M-100 standard is recognized

-

-

-

Bacteroides fragilis

≤8/4

16/4

≥32/4

-

-

-

Haemophilus influenzae

M-100 standard is recognized

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

STIC are based on a dose for adults of 1.5g every 8 h for the treatment of complicated intra-abdominal infections and complicated urinary tract infections or a dose of 3 g every 8 h for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Back to Top